ReviewAdvanced healthcare materials2026
Engineering Advanced Nanomedicine Against Depression: From Treatment Challenges to Delivery Strategies.
Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Depression is a leading global health burden, yet current pharmacotherapy remains constrained by depression-specific challenges that extend beyond simple blood-brain barrier (BBB) penetration, including delayed onset of action, poor regional brain specificity, and the inability to deliver emerging biologics. Engineered nanomedicine offers a paradigm-shifting platform to address these limitations through precise designs such as receptor-mediated transport and cell-mimetic carriers, enabling targeted modulation of depression-related neural circuits. This review critically evaluates advanced nanoengineering strategies for antidepressant delivery, distinguishing proof-of-concept systems from platforms with realistic translational potential. We further provide a decision-oriented framework to guide future clinical development. By moving beyond generic strategies for BBB penetration to address the distinctive pharmacotherapeutic shortcomings of depression, engineered nanomedicine holds great promise for advancing next-generation antidepressant therapies that achieve rapid onset, precise intervention, and comprehensive improvement in patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.